What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models
Open Access
- 1 May 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 20 (5), 740-750
- https://doi.org/10.1158/1055-9965.epi-10-0718
Abstract
Background: Making an informed decision about treating a prostate cancer detected after a routine prostate-specific antigen (PSA) test requires knowledge about disease natural history, such as the chances that it would have been clinically diagnosed in the absence of screening and that it would metastasize or lead to death in the absence of treatment. Methods: We use three independently developed models of prostate cancer natural history to project risks of clinical progression events and disease-specific deaths for PSA-detected cases assuming they receive no primary treatment. Results: The three models project that 20%–33% of men have preclinical onset; of these 38%–50% would be clinically diagnosed and 12%–25% would die of the disease in the absence of screening and primary treatment. The risk that men age less than 60 at PSA detection with Gleason score 2–7 would be clinically diagnosed in the absence of screening is 67%–93% and would die of the disease in the absence of primary treatment is 23%–34%. For Gleason score 8 to 10 these risks are 90%–96% and 63%–83%. Conclusions: Risks of disease progression among untreated PSA-detected cases can be nontrivial, particularly for younger men and men with high Gleason scores. Model projections can be useful for informing decisions about treatment. Impact: This is the first study to project population-based natural history summaries in the absence of screening or primary treatment and risks of clinical progression events following PSA detection in the absence of primary treatment. Cancer Epidemiol Biomarkers Prev; 20(5); 740–50. ©2011 AACR.Other Versions
This publication has 33 references indexed in Scilit:
- Calibrating disease progression models using population data: a critical precursor to policy development in cancer controlBiostatistics, 2010
- Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–RotterdamJNCI Journal of the National Cancer Institute, 2010
- Stage‐specific cancer incidence: An artificially mixed multinomial logit modelStatistics in Medicine, 2009
- Mortality Results from a Randomized Prostate-Cancer Screening TrialThe New England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyThe New England Journal of Medicine, 2009
- Lead Time and Overdiagnosis in Prostate-Specific Antigen Screening: Importance of Methods and ContextJNCI Journal of the National Cancer Institute, 2009
- Quantifying the role of PSA screening in the US prostate cancer mortality declineCancer Causes & Control, 2007
- Predicting survival for men with clinically localized prostate cancerCancer, 2007
- Nomogram incorporating PSA level to predict cancer‐specific survival for men with clinically localized prostate cancer managed without curative intentCancer, 2007
- A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survivalBritish Journal of Cancer, 2006